Endometriosis is a common chronic gynecological disease defined by the growth of endometrial tissue outside the uterine cavity, with a global incidence of 10%–15% in reproductive-age women, and up to 40%–50% in infertile women.
It is divided into 3 main types: ovarian endometrioma, peritoneal endometriosis, and deep infiltrating endometriosis (DIE). Core symptoms include progressive dysmenorrhea, chronic pelvic pain, dyspareunia, and infertility. DIE can invade the bowel, ureter, and bladder, leading to severe organ dysfunction. The disease has the characteristics of high recurrence rate (up to 50% within 5 years after surgery), hormone dependence, and malignant transformation risk, seriously affecting women's quality of life and reproductive function.
China has the largest number of DIE surgery cases in the world, with a laparoscopic minimally invasive surgery rate of over 90%. The success rate of radical DIE resection with bowel/ureter/bladder involvement exceeds 98%, on par with top European and American centers, and the postoperative pain relief rate reaches 95%.
Top centers have original "surgery + adjuvant drug + ART" integrated management system for endometriosis-related infertility, with a postoperative natural pregnancy rate of over 40%, and a live birth rate of over 55% with combined ART, leading the global average.
China's original personalized long-term management protocol reduces the 5-year recurrence rate to below 20%, far lower than the global average of 50%. The integrated traditional Chinese and Western medicine treatment for chronic pelvic pain has an effective rate of over 85%, a unique advantage of Chinese treatment.
The cost of laparoscopic DIE radical surgery in top Chinese centers is only 5,000–8,000 USD, which is 1/4–1/3 of that in the US (20,000–30,000 USD). The waiting time for surgery is only 1–2 weeks, while it often takes 3–6 months in European and American centers.
